These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38560158)

  • 1. Development of a robust cell-based potency assay for a coxsackievirus A21 oncolytic virotherapy.
    Chamcha V; He L; Jenny Xu ; Swartz AR; Green-Trexler E; Gurney K; McNeely T
    Heliyon; 2024 Apr; 10(7):e28414. PubMed ID: 38560158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering Oncolytic Coxsackievirus A21 with Small Transgenes and Enabling Cell-Mediated Virus Delivery by Integrating Viral cDNA into the Genome.
    Sam M; Selman M; Zhao W; Jung J; Willingham A; Phan U; Starling GC; Gao Q
    J Virol; 2023 May; 97(5):e0030923. PubMed ID: 37070982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy.
    Burnett WJ; Burnett DM; Parkman G; Ramstead A; Contreras N; Gravley W; Holmen SL; Williams MA; VanBrocklin MW
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Applications of coxsackievirus A21 in oncology.
    Bradley S; Jakes AD; Harrington K; Pandha H; Melcher A; Errington-Mais F
    Oncolytic Virother; 2014; 3():47-55. PubMed ID: 27512662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
    Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
    J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Activity of Targeted Picornaviruses Formulated as Synthetic Infectious RNA.
    Elsedawy NB; Nace RA; Russell SJ; Schulze AJ
    Mol Ther Oncolytics; 2020 Jun; 17():484-495. PubMed ID: 32529026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitation of Coxsackievirus A21 Viral Proteins in Mixtures of Empty and Full Capsids Using Capillary Western.
    Gillespie PF; Rustandi RR; Swartz AR; Shang L; Raffaele J; Prout A; Cunningham N; Dawod M; Deng JZ; Wang S; Olson J; Shieh Y; Loughney JW
    Hum Gene Ther; 2023 Jan; 34(1-2):68-77. PubMed ID: 36503264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a Cell-Based Reporter Potency Assay for Live Virus Vaccines.
    Sun D; Meyer BK; Deevi DS; Mirza A; He L; Gruber A; Abbondanzo SJ; Benton NA; Whiteman MC; Capen RC; Gurney KB
    Vaccines (Basel); 2024 Jul; 12(7):. PubMed ID: 39066407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus: Using a Bladder Tumor Precision-Cut Slice Model System to Assess Viral Efficacy.
    Relph K; Annels N; Smith C; Kostalas M; Pandha H
    Methods Mol Biol; 2020; 2058():249-259. PubMed ID: 31486043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated, label-free TCID
    Hochdorfer D; Businger R; Hotter D; Seifried C; Solzin J
    J Virol Methods; 2022 Jan; 299():114318. PubMed ID: 34626683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma.
    Au GG; Lincz LF; Enno A; Shafren DR
    Br J Haematol; 2007 Apr; 137(2):133-41. PubMed ID: 17391493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SEC coupled with in-line multiple detectors for the characterization of an oncolytic Coxsackievirus.
    Deng JZ; Rustandi RR; Swartz A; Shieh Y; Baker JB; Vlasak J; Wang S; Loughney JW
    Mol Ther Oncolytics; 2022 Mar; 24():139-147. PubMed ID: 35024440
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells.
    Holmes M; Scott GB; Heaton S; Barr T; Askar B; Müller LME; Jennings VA; Ralph C; Burton C; Melcher A; Hillmen P; Parrish C; Errington-Mais F
    Mol Ther Oncolytics; 2023 Jun; 29():17-29. PubMed ID: 37077714
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus.
    Annels NE; Arif M; Simpson GR; Denyer M; Moller-Levet C; Mansfield D; Butler R; Shafren D; Au G; Knowles M; Harrington K; Vile R; Melcher A; Pandha H
    Mol Ther Oncolytics; 2018 Jun; 9():1-12. PubMed ID: 29989024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oncolytic coxsackievirus therapy as an immunostimulator].
    Miyamoto S; Sagara M; Kohara H; Tani K
    Rinsho Ketsueki; 2017; 58(8):977-982. PubMed ID: 28883283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutathione affinity chromatography for the scalable purification of an oncolytic virus immunotherapy from microcarrier cell culture.
    Swartz AR; Shieh Y; Gulasarian A; Curtis E; Hofmann CF; Baker JB; Templeton N; Olson JW
    Front Bioeng Biotechnol; 2023; 11():1193454. PubMed ID: 37397964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced oncolysis mediated by Coxsackievirus A21 in combination with doxorubicin hydrochloride.
    Skelding KA; Barry RD; Shafren DR
    Invest New Drugs; 2012 Apr; 30(2):568-81. PubMed ID: 21170760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Infectious SARS-CoV-2 by the 50% Tissue Culture Infectious Dose Endpoint Dilution Assay.
    Bullen CK; Davis SL; Looney MM
    Methods Mol Biol; 2022; 2452():131-146. PubMed ID: 35554905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
    Marchini A; Scott EM; Rommelaere J
    Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloma xenograft destruction by a nonviral vector delivering oncolytic infectious nucleic acid.
    Hadac EM; Kelly EJ; Russell SJ
    Mol Ther; 2011 Jun; 19(6):1041-7. PubMed ID: 21505425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.